Glaukos has entered a global exclusive license to research, develop, manufacture and commercialise a patented, noninvasive drug delivery platform designed by Intratus Inc. The platform has potential to be used in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.
Intratus’ patented cream-based drug formulations are applied to the outer surface of the eyelid for transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. Early human studies with this novel delivery system have demonstrated efficacy without the side effects often associated with drugs delivered as topical eye drops.
“This licensing agreement adds a novel drug delivery platform using a differentiated, non-invasive transdermal approach to our expanding portfolio of sustained pharmaceutical systems,” said Thomas Burns, Glaukos president and chief executive officer.
He said Intratus’ proprietary transdermal drug delivery application was highly complementary to Glaukos’ expanding portfolio of sustained pharmaceutical systems.
